• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


Long-term PAS

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Inadequate
Application Number P100006 S005/ PAS001
Date Current Protocol Accepted 06/11/2019
Study Name Long-term PAS
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Concurrent Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description The study is designed to assess the long-term (out to 6 years post-op) performance of AUGMENT Injectable compared to autograft by continued follow-up of available subjects from several prospective clinical studies (protocols BMTI-2009-01, BMTI-2010-01, and BMTI-2006-01 (autograft only)). No new subjects will be enrolled. Subjects and radiologists will remain blinded. Subjects will be informed of their treatment after the last evaluation.
Study is intended to address the following questions:
Can it be assessed and confirmed that bridging bone occurs in the long-term after AUGMENT® Injectable has been resorbed?
Are the improvements in clinical outcomes associated with the use of AUGMENT® Injectable sustained long-term?
Does the promotion of existing tumors from a nonmalignant to malignant state at longer time-points in patients treated with AUGMENT® Injectable exceed the expected rate of promotion in patients not treated with AUGMENT® Injectable or other growth factors used to promote fusion?
Study Population Description study group: AUGMENT Injectable graft with fused joints stabilized by metallic fixation hardware
control group: autograft with fused joints stabilized by metallic fixation hardware
Sample Size 88 projected from 179 potential prior subjects
actual sample size may be modified to address discrepancies
Data Collection Primary Effectiveness Endpoints:
Pain on weight bearing (via VAS)
Confirmation of bridging bone via CT
Subject function as determined by AOFAS, FFI
Primary Safety Endpoints:
Presence of all treatment related adverse events (i.e., description, frequency, incidence, time to onset of first event, severity, duration, treatments administered, etc.)
Presence of serious unanticipated adverse device effects
rhPDGF-BB antibody status
Significant medical conditions, including incidence of cancer
Presence of clinically important events
Functional Assessments
Subjects will assessed using the pain, function and quality of life data instruments:
Fusion Site Pain via VAS score (FSP)
Weight Bearing Pain Assessment at Fusion Site via VAS score (WBP)
Graft Harvest Site Pain via VAS score (GHSP)
Foot Pain and Disability Index (FFI)
AOFAS Hindfoot/Ankle Score (AOFAS)
Safety Assessments
Subjects will be assessed for safety parameters and events, including:
Presence of all treatment related adverse events
Presence of serious unanticipated adverse device effects (UADE)
rhPDGF-BB antibody status
Presence of clinically important events as defined below:
- Musculoskeletal and connective tissue disorders (severe pain,
swelling and/or arthralgia in the treated foot/ankle joint(s));
- Additional surgery of the original treated joint due to non-union.
- Neoplasms benign, malignant and unspecified (including cysts
and polyps) (all lower level terms associated with neoplasms)
- Complications related to bone graft harvest site
Follow-up Visits and Length of Follow-up Subjects will be followed out to at least 5 years post-op
Interim or Final Data Summary
Interim Safety Information Based on the small amount of data available, the longer-term clinical outcomes and rates and
types of adverse events appear to be comparable between the two study groups.
Actual Number of Patients Enrolled 45
Actual Number of Sites Enrolled 15
Patient Follow-up Rate overall: 46/168 (27.4%)
Augment Injectable: 33/123 (26.8%)
Autograft bone control: 13/45 (28.9%)
Study Strengths & Weaknesses Because the subjects were enrolled over an extended period of time and the study has not been
completed, final conclusions of longer-term effectiveness and safety cannot yet be made.

Long-term PAS Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
6 month report 12/11/2018 12/11/2018 On Time
1 year report 06/12/2019 06/10/2019 On Time
18 month report 12/12/2019 12/06/2019 On Time
2 year report 06/11/2020 06/10/2020 On Time
3 year report 06/11/2021 06/11/2021 On Time
4 year report 06/11/2022 06/07/2022 On Time
5 year report 06/11/2023    

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources